146 related articles for article (PubMed ID: 34693877)
1. Computational investigation of ginkgetin and theaflavin as potential inhibitors of heat shock protein 90 (Hsp90).
Bhadresha K; Upadhyay V; Kumar SP; Pandya P; Jain N; Rawal RM
J Biomol Struct Dyn; 2022; 40(24):13675-13681. PubMed ID: 34693877
[TBL] [Abstract][Full Text] [Related]
2. Theaflavin-3-gallate, a natural antagonist for Hsp90: In-silico and in-vitro approach.
Bhadresha K; Kumar SP; Brahmbhatt J; Patel C; Pandya P; Jain N; Rawal R
Chem Biol Interact; 2022 Feb; 353():109774. PubMed ID: 34958756
[TBL] [Abstract][Full Text] [Related]
3. In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations.
Rezvani S; Ebadi A; Razzaghi-Asl N
J Biomol Struct Dyn; 2022; 40(21):10665-10676. PubMed ID: 34286666
[TBL] [Abstract][Full Text] [Related]
4. New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics studies.
Abbasi M; Amanlou M; Aghaei M; Bakherad M; Doosti R; Sadeghi-Aliabadi H
J Biomol Struct Dyn; 2020 Aug; 38(12):3462-3473. PubMed ID: 31452440
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
6. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
[TBL] [Abstract][Full Text] [Related]
7. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
[TBL] [Abstract][Full Text] [Related]
8.
Dike PP; Bhowmick S; Eldesoky GE; Wabaidur SM; Patil PC; Islam MA
J Biomol Struct Dyn; 2022 Mar; 40(5):2082-2098. PubMed ID: 33095103
[TBL] [Abstract][Full Text] [Related]
9. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
10. Identification of the naphthoquinone derivative inhibitors binding site in heat shock protein 90: an induced-fit docking, molecular dynamics and 3D-QSAR study.
Godoy-Castillo C; Bravo-Acuña N; Arriagada G; Faunes F; León R; Soto-Delgado J
J Biomol Struct Dyn; 2021 Oct; 39(16):5977-5987. PubMed ID: 32799638
[TBL] [Abstract][Full Text] [Related]
11. Strategy of Virtual Screening based Discovery of HSP90 C-terminal Inhibitors and Network Pharmacological Analysis.
Li L; Yang M; Li C; Xue H; Shi M; Liu Y
Curr Pharm Biotechnol; 2022; 23(14):1637-1646. PubMed ID: 34514987
[TBL] [Abstract][Full Text] [Related]
12. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
[TBL] [Abstract][Full Text] [Related]
13. Understanding conformational diversity of heat shock protein 90 (HSP90) and binding features of inhibitors to HSP90 via molecular dynamics simulations.
Yan F; Liu X; Zhang S; Zhang Q; Chen J
Chem Biol Drug Des; 2020 Jan; 95(1):87-103. PubMed ID: 31560152
[TBL] [Abstract][Full Text] [Related]
14. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
Rampogu S; Parate S; Parameswaran S; Park C; Baek A; Son M; Park Y; Park SJ; Lee KW
Comput Biol Chem; 2019 Dec; 83():107113. PubMed ID: 31493740
[TBL] [Abstract][Full Text] [Related]
15. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
[TBL] [Abstract][Full Text] [Related]
16. Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90).
Mak OW; Chand R; Reynisson J; Leung IKH
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31717777
[TBL] [Abstract][Full Text] [Related]
17. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking and dynamics simulation study of quinones and pyrones from
H N K; Murali Sharma P; Garampalli RH
J Biomol Struct Dyn; 2023; 41(24):14744-14756. PubMed ID: 36935093
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90.
Li L; Yang M; Li C; Liu Y
Naunyn Schmiedebergs Arch Pharmacol; 2021 Nov; 394(11):2223-2232. PubMed ID: 34406420
[TBL] [Abstract][Full Text] [Related]
20. Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening.
Jia J; Xu X; Liu F; Guo X; Zhang M; Lu M; Xu L; Wei J; Zhu J; Zhang S; Zhang S; Sun H; You Q
PLoS One; 2013; 8(4):e59315. PubMed ID: 23565147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
